Novolog, Novorapid(insulin aspart)
Fiasp, NovoMix, NovoRapid, Novolog, Ryzodeg (insulin aspart) is a protein pharmaceutical. Insulin aspart was first approved as Novorapid on 1999-09-07. It has been approved in Europe to treat diabetes mellitus.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Fiasp, Novolog
CombinationsNovolog mix (discontinued: Ryzodeg)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Insulin aspart
Insulin aspart
+
Insulin aspart protamine
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Novolog Mix 70/30 | insulin aspart protamine and insulin aspart | Novo Nordisk Inc. | N-21172 RX | 2001-11-01 | 2 products |
Show 2 discontinued
Insulin aspart
+
Insulin degludec
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Ryzodeg 70/30 | insulin degludec and insulin aspart | Novo Nordisk Inc. | N-203313 DISCN | 2015-09-25 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fiasp | Biologic Licensing Application | 2019-12-19 |
| novolog mix 70/30 | Biologic Licensing Application | 2023-02-04 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10A: Insulins and analogues
— A10AB: Insulins and analogues for injection, fast-acting
— A10AB05: Insulin aspart
— A10AD: Insulins and analogues for injection used in diabetes, intermediate- or long-acting combined with fast-acting
— A10AD05: Insulin aspart
— A10AD06: Insulin degludec and insulin aspart
HCPCS
No data
Clinical
Clinical Trials
452 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 14 | 8 | 61 | 70 | 58 | 210 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 57 | 10 | 50 | 34 | 48 | 196 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 2 | 2 | 6 | 2 | 6 | 17 |
| Hyperglycemia | D006943 | HP_0003074 | R73.9 | — | — | — | 4 | 3 | 7 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | — | 1 | 1 | 2 | — | 3 |
| Gestational diabetes | D016640 | HP_0009800 | O24.4 | — | — | 1 | 1 | — | 2 |
| Hyperkalemia | D006947 | HP_0002153 | E87.5 | — | — | — | 1 | — | 1 |
| Coronary artery disease | D003324 | I25.1 | — | — | — | 1 | — | 1 | |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | 1 | — | 1 |
| Arteriosclerosis | D001161 | EFO_0009086 | I70 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | 1 | — | 1 | 2 |
| Pregnancy complications | D011248 | — | — | 1 | — | — | 1 | ||
| Diabetes complications | D048909 | — | 1 | 1 | — | — | 1 | ||
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 1 | — | — | 1 |
| Leukemia | D007938 | C95 | — | — | 1 | — | — | 1 | |
| Lymphoma | D008223 | C85.9 | — | — | 1 | — | — | 1 | |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | 1 | — | — | 1 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | 1 | 1 | — | — | 1 | |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 1 | — | — | 1 |
| Pharmacokinetics | D010599 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 2 | 1 | — | — | — | 2 |
| Cognitive dysfunction | D060825 | G31.84 | 1 | 1 | — | — | — | 2 | |
| Exercise | D015444 | EFO_0000483 | — | 1 | — | — | — | 1 | |
| Delirium | D003693 | R41.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 22 | — | — | — | — | 22 | ||
| Diabetic retinopathy | D003930 | EFO_0003770 | 1 | — | — | — | — | 1 | |
| Olfaction disorders | D000857 | R43.0 | 1 | — | — | — | — | 1 | |
| Taste disorders | D013651 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | — | 2 | 2 |
| Congenital hyperinsulinism | D044903 | — | — | — | — | 1 | 1 | ||
| Diabetic ketoacidosis | D016883 | EFO_1000897 | — | — | — | — | 1 | 1 | |
| Chronic renal insufficiency | D051436 | N18 | — | — | — | — | 1 | 1 | |
| Latent autoimmune diabetes in adults | D000071698 | — | — | — | — | 1 | 1 | ||
| Infections | D007239 | EFO_0000544 | — | — | — | — | 1 | 1 | |
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 | |
| Fetal macrosomia | D005320 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | INSULIN ASPART |
| INN | insulin aspart |
| Description | Insulin aspart |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 116094-23-6 |
| RxCUI | 51428 |
| ChEMBL ID | CHEMBL1201496 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB01306 |
| UNII ID | D933668QVX (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Novorapid - Novo Nordisk
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Ryzodeg - Novo Nordisk
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Novomix - Novo Nordisk
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Fiasp - Novo Nordisk
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,983 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,374 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more